SEC Tracker
Get the app

Vaxcyte PCVX

Vaxcyte announces positive trial results for VAX-31

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. VAX-31 met all primary endpoints in OPUS-1 trial
  2. Company expects BLA submission in 2028
  3. Pro forma cash of $3.4 billion as of September 2026

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Vaxcyte files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. PERRIGO PRGO public float $3.7B, Jun 27, 2025
  2. Rhythm Pharmaceuticals RYTM public float $3.8B, Jun 30, 2025
  3. Ultragenyx Pharmaceutical RARE public float $3.4B, Jun 30, 2025
  4. Avidity Biosciences RNAM public float $3.4B, Jun 30, 2025
  5. Soleno Therapeutics SLNO public float $4.1B, Jun 30, 2025